Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
275M
-
Number of holders
-
85
-
Total 13F shares, excl. options
-
130M
-
Shares change
-
-1.15M
-
Total reported value, excl. options
-
$230M
-
Value change
-
-$12.4M
-
Put/Call ratio
-
0.3
-
Number of buys
-
55
-
Number of sells
-
-18
-
Price
-
$1.77
Significant Holders of Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) as of Q4 2023
97 filings reported holding TSHA - Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value as of Q4 2023.
Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) has 85 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 130M shares
of 275M outstanding shares and own 47.36% of the company stock.
Largest 10 shareholders include FMR LLC (22.4M shares), RA CAPITAL MANAGEMENT, L.P. (18.5M shares), RTW INVESTMENTS, LP (16.9M shares), VR Adviser, LLC (10.4M shares), VANGUARD GROUP INC (6.2M shares), Avoro Capital Advisors LLC (4.36M shares), BAKER BROS. ADVISORS LP (4M shares), Eversept Partners, LP (3.78M shares), TYBOURNE CAPITAL MANAGEMENT (HK) LTD (3.7M shares), and Artal Group S.A. (3.66M shares).
This table shows the top 85 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.